Precision BioSciences (DTIL) Tops Q1 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
Precision BioSciences Reports First Quarter and 2021 Financial Results and Provides Business Update
May 13, 2021 7:00 AM EDT- Reacquired Global Development and Commercialization Rights to all Servier Partnered CAR T Programs, Including PBCAR0191 and PBCAR19B Stealth Cell
- Expect to Present Updated PBCAR0191 Data in June at ASCO 2021
- Plan to Initiate Phase 1 Study of PBCAR19B Stealth Cell in Patients with R/R NHL by End of May 2021
- Appointed Alan List, M.D. as Chief Medical Officer and Stanley Frankel, M.D. to Board of Directors; Initiated CEO Transition Plan to Support Companys Next Phase of... More
